Pappone Carlo, Negro Gabriele, Ciconte Giuseppe
Vita-Salute San Raffaele University, Piazza Malan 2, 20097 Milano, Italy.
Arrhythmia and Electrophysiology Center, IRCCS Policlinico San Donato, San Donato Milanese, Milano, Italy.
Eur Heart J Suppl. 2021 Oct 8;23(Suppl E):E112-E117. doi: 10.1093/eurheartj/suab104. eCollection 2021 Oct.
Sudden cardiac death (SCD) is a relevant contributor to cardiovascular mortality, often occurring as a dramatic event. It can be the consequence of a ventricular tachycardia/fibrillation (VT/VF), a common and life-threatening arrhythmia. The underlying mechanisms of this catastrophic arrhythmia are poorly known. In fact, it can occur in the presence of a structural heart condition which itself generates the suitable substrate for this arrhythmia. Nevertheless, a VF may cause SCD also in young and otherwise healthy individuals, without overt structural abnormalities, generating difficulties in the screening and prevention of these patients. The implantable cardioverter-defibrillator represents the only therapy to contrast SCD by treating a VT/VF; however, it cannot prevent the occurrence of such arrhythmias. Catheter ablation is emerging as an essential therapeutic tool in the management of patients experiencing ventricular arrhythmias.
心脏性猝死（SCD）是心血管疾病死亡率的一个重要因素，通常表现为突发的严重事件。它可能是室性心动过速/心室颤动（VT/VF）的结果，这是一种常见且危及生命的心律失常。这种灾难性心律失常的潜在机制尚不清楚。事实上，它可能发生在存在结构性心脏病的情况下，而结构性心脏病本身就为这种心律失常产生了合适的基质。然而，VF也可能在年轻且无明显结构异常的健康个体中导致SCD，这给这些患者的筛查和预防带来了困难。植入式心脏复律除颤器是通过治疗VT/VF来对抗SCD的唯一疗法；然而，它无法预防此类心律失常的发生。导管消融正在成为治疗室性心律失常患者的一种重要治疗手段。
